» Articles » PMID: 8528601

Pharmacological Modulation of IL-6 and IL-8 Secretion by the H1-antagonist Decarboethoxy-loratadine and Dexamethasone by Human Mast and Basophilic Cell Lines

Overview
Journal Exp Dermatol
Specialty Dermatology
Date 1995 Aug 1
PMID 8528601
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Mast cells and basophils are central effector cells of allergic reactions and are involved in inflammatory diseases. These cell types produce an array of mediators including a broad spectrum of cytokines. In order to examine whether antiallergic drugs modulate the release of these mediators, we have investigated the influence of dexamethasone and decarboethoxy-loratadine (DEL), the active metabolite of the H1-blocking agent loratadine, on the release of IL-6 and IL-8 by the human mast cell line HMC-1 and the human basophilic cell line KU812 by ELISA. Dexamethasone (10(-6)-10(-11) M) or Del (10(-5)-10(-14) M) were added to the cells either 1 h prior to or simultaneously with PMA and Ca-ionophore A23187. When preincubated with the cells, DEL dose-dependently suppressed IL-6 release by up to 40% and IL-8 release by up to 50%. Dexamethasone potently suppressed secretion of both cytokines if simultaneously added to the cells with the stimuli by up to 60% and after preincubation by up to 80%. Since both antihistamines and glucocorticoids are used for treatment of allergic diseases, the findings reported here indicate that these drugs may modulate allergic reactions via inhibition of cytokine release from mast cells and basophils.

Citing Articles

Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial.

Wandalsen G, Miranda C, Ensina L, Sano F, Amazonas R, da Silva J Braz J Otorhinolaryngol. 2016; 83(6):633-639.

PMID: 27670203 PMC: 9449020. DOI: 10.1016/j.bjorl.2016.08.009.


Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence.

Canonica G, Blaiss M World Allergy Organ J. 2012; 4(2):47-53.

PMID: 23268457 PMC: 3500039. DOI: 10.1097/WOX.0b013e3182093e19.


Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells.

Mullol J, de Borja Callejas F, Martinez-Anton M, Mendez-Arancibia E, Alobid I, Pujols L Respir Res. 2011; 12:23.

PMID: 21352574 PMC: 3056736. DOI: 10.1186/1465-9921-12-23.


[Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series].

Schulz S, Metz M, Siepmann D, Luger T, Maurer M, Stander S Hautarzt. 2009; 60(7):564-8.

PMID: 19430742 DOI: 10.1007/s00105-009-1730-4.


Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Devillier P, Roche N, Faisy C Clin Pharmacokinet. 2008; 47(4):217-30.

PMID: 18336052 DOI: 10.2165/00003088-200847040-00001.